Cornerstone Investment Partners LLC Makes New Investment in IQVIA Holdings Inc. $IQV

Cornerstone Investment Partners LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, HoldingsChannel reports. The fund purchased 282,378 shares of the medical research company’s stock, valued at approximately $44,500,000. IQVIA comprises approximately 2.0% of Cornerstone Investment Partners LLC’s holdings, making the stock its 28th biggest position.

Several other hedge funds have also modified their holdings of the stock. Brighton Jones LLC increased its holdings in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of IQVIA by 15.9% during the first quarter. Envestnet Asset Management Inc. now owns 482,680 shares of the medical research company’s stock worth $85,096,000 after buying an additional 66,169 shares during the period. Crossmark Global Holdings Inc. raised its holdings in IQVIA by 2.3% in the first quarter. Crossmark Global Holdings Inc. now owns 14,696 shares of the medical research company’s stock valued at $2,591,000 after acquiring an additional 334 shares in the last quarter. Stratos Wealth Partners LTD. lifted its stake in IQVIA by 13.0% in the first quarter. Stratos Wealth Partners LTD. now owns 6,468 shares of the medical research company’s stock worth $1,140,000 after acquiring an additional 743 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in IQVIA by 20.3% during the 1st quarter. Nisa Investment Advisors LLC now owns 13,030 shares of the medical research company’s stock worth $2,297,000 after acquiring an additional 2,195 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on IQV shares. Stifel Nicolaus raised their price objective on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Evercore ISI raised their price target on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th. Citigroup upped their price objective on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and upped their price target for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $239.94.

IQVIA Stock Up 0.6%

Shares of NYSE IQV opened at $211.29 on Friday. The stock has a market cap of $35.98 billion, a PE ratio of 28.98, a price-to-earnings-growth ratio of 2.35 and a beta of 1.34. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $225.91. The business has a 50-day moving average price of $198.98 and a 200 day moving average price of $175.59. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.